Literature DB >> 22934271

Tumor conditioned media from colorectal cancer patients inhibits dendritic cell maturation.

Adriana J Michielsen1, Jacintha N O'Sullivan, Elizabeth J Ryan.   

Abstract

Tumors inhibit dendritic cell maturation and function in order to evade host immunity. We showed that conditioned media from tumor explant tissue, taken from metastatic colorectal cancer patients, significantly inhibits maturation of dendritic cells.

Entities:  

Year:  2012        PMID: 22934271      PMCID: PMC3429583          DOI: 10.4161/onci.19570

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


Tumors are poorly immunogenic and are capable of evading the immune system. Dendritic cells (DCs) are professional antigen presenting cells. Immature DCs detect and capture antigens and subsequently undergo a maturation process, which enables them to present the antigens to other immune cells such as T-cells. In addition, DCs secrete cytokines to promote the appropriate immune response to the pathogen/tumor. To elucidate the effect of the tumor microenvironment on DC function, we used a human colorectal cancer explant model. Tumour tissue and adjacent normal tissue were collected from colorectal cancer patients undergoing surgery in St. Vincent’s University Hospital, Dublin. We generated tumor conditioned media (TCM) and normal conditioned media (NCM) by culturing the tumor and adjacent normal tissue for 72 hours. Monocyte derived DCs obtained from healthy controls were treated with the TCM of 21 colorectal cancer patients in the absence or presence of LPS. Levels of maturation markers expressed by DCs were analyzed by flow cytometry and cytokine secretion was measured by ELISA. We found that TCM significantly reduced the LPS-induced upregulation of CD86, CD83, HLA-DR and CD54. In addition, TCM reduced IL-12p70 and increased IL-10 secretions induced by LPS (Fig. 1): a phenotype associated with tolerance. In contrast, NCM did not significantly affect DC maturation, indicating that the normal adjacent mucosa has functional immunity.

Figure 1. The tumor microenvironment inhibits dendritic cell maturation and function in response to LPS. Tumors produce a large array of soluble factors, which inhibit LPS induced dendritic cell (DC) maturation (A). In addition, they affect DC function by increasing IL-10 and decreasing IL-12p70 secretion (B). VEGF, CCL2, CXCL1 and CXCL5, which are secreted at high levels by the tumor, affect DC function by inhibiting LPS induced IL-12p70 secretion (C).

Figure 1. The tumor microenvironment inhibits dendritic cell maturation and function in response to LPS. Tumors produce a large array of soluble factors, which inhibit LPS induced dendritic cell (DC) maturation (A). In addition, they affect DC function by increasing IL-10 and decreasing IL-12p70 secretion (B). VEGF, CCL2, CXCL1 and CXCL5, which are secreted at high levels by the tumor, affect DC function by inhibiting LPS induced IL-12p70 secretion (C). While other studies have shown that conditioned media from single cell cultures have similar inhibitory effects,- this is the first study to use a 3D explant model which mimics the complex structure and composition of a tumor, including the stroma. A big advantage of this model is that it more closely reflects the inflammatory milieu of the tumor than cancer cell lines, and therefore would be a good model for screening potential new drugs and biomarkers. We screened the TCM to determine which factors present mediated DC inhibition. VEGF, a growth factor that promotes angiogenesis and has been reported to inhibit DC maturation and function, was present at high levels in the TCM. In addition, we found high levels of CCL2 (MCP-1), CXCL1 (GROα) and CXCL5 (ENA-78) were secreted by all tumors. The main function of CCL2 is to attract monocytes and macrophages, while CXCL1 and CXCL5 attract and activate neutrophils. While all of these chemokines can promote tumor growth, proliferation and angiogenesis,, how they affect DCs has not been investigated. Therefore we exposed monocyte derived DCs obtained from healthy donors to recombinant VEGF (which acts as our positive control for DC inhibition) CCL2, CXCL1 and CXCL5 prior to stimulation with LPS. VEGF and all 3 chemokines reduced LPS-induced secretion of IL-12p70 (Fig. 1), thereby reducing the possibility of a potent Th1 response. VEGF inhibited LPS-induced expression of CD54 and CD80, while CXCL1 inhibited HLA-DR expression, indicating that they, to some extent, affect DC maturation. However, LPS-induced IL-10, IL-1β, TNFα, IL-8 and IL-6 secretion was not affected. Neither did CCL2, CXCL1, CXCL5 or VEGF affect DC migration, T-cell proliferation or IFNγ production from T-cells. These results show that these chemokines alone are not the only factors in the TCM that inhibit DCs; however they contribute to the immunosuppressive environment by reducing IL-12p70 secretion from DCs. Furthermore, these chemokines may work synergistically to inhibit DC maturation and function. To test this we combined the cytokines, we found that CXCL1 and VEGF had an additive effect on the LPS-induced inhibition of IL-12p70 secretion from DCs. However, when CXCL1 and VEGF were neutralised in the TCM, either alone or together, the inhibitory effect of the TCM was not reversed. These results show that it is very likely that it is not a single agent but multiple factors present in the TCM affect DC maturation and function. Timing of the exposure of DCs to tumor derived cytokines is important. While we did not study the effects of CCL2, CXCL1, CXCL5 and VEGF on DC differentiation, other studies have shown that the presence of VEGF, IL-6, G-CSF or prostanoids during the differentiation stage significantly inhibit DC function.- Moreover, neutralisation of IL-6 or G-CSF in conditioned media of the pancreatic cancer cell line BxPC-3 significantly reversed its inhibitory effects. Inhibition of COX1/2 in primary colon tumor cells supernatants, which results in reduced prostanoid production, also significantly reversed the inhibitory effects of the conditioned media; however neither induced a complete reversion. These results also illustrate that multiple factors secreted by the tumor are responsible for inhibiting DC differentiation in addition to DC maturation and function. In summary, we show that the TCM components CCL2, CXCL1, CXCL5 and VEGF play a role in modulating the inflammatory response through inhibition of IL-12p70 secretion by DCs, a novel strategy employed by the tumor to evade the immune response. In addition, CXCL1 and VEGF act together in the inhibition of IL-12p70 secretion from DCs. Even though CCL2, CXCL1, CXCL5 and VEGF are abundantly present in the TCM, they may not be the most biologically active in affecting DC maturation and function. It is probable that the action of the entire tumor microenvironment is required to elicit such a significant effect.
  8 in total

Review 1.  Immunobiology of dendritic cells.

Authors:  J Banchereau; F Briere; C Caux; J Davoust; S Lebecque; Y J Liu; B Pulendran; K Palucka
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

2.  Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation.

Authors:  Claudia C Sombroek; Anita G M Stam; Allan J Masterson; Sinéad M Lougheed; Marcel J A G Schakel; Chris J L M Meijer; Herbert M Pinedo; Alfons J M van den Eertwegh; Rik J Scheper; Tanja D de Gruijl
Journal:  J Immunol       Date:  2002-05-01       Impact factor: 5.422

Review 3.  CCL2 (monocyte chemoattractant protein-1) and cancer.

Authors:  Ilaria Conti; Barrett J Rollins
Journal:  Semin Cancer Biol       Date:  2004-06       Impact factor: 15.707

4.  Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells.

Authors:  D I Gabrilovich; H L Chen; K R Girgis; H T Cunningham; G M Meny; S Nadaf; D Kavanaugh; D P Carbone
Journal:  Nat Med       Date:  1996-10       Impact factor: 53.440

Review 5.  The chemokine network in cancer--much more than directing cell movement.

Authors:  Hagen Kulbe; Neil R Levinson; Fran Balkwill; Julia L Wilson
Journal:  Int J Dev Biol       Date:  2004       Impact factor: 2.203

6.  Elevated interleukin-6 and G-CSF in human pancreatic cancer cell conditioned medium suppress dendritic cell differentiation and activation.

Authors:  Uddalak Bharadwaj; Min Li; Rongxin Zhang; Changyi Chen; Qizhi Yao
Journal:  Cancer Res       Date:  2007-06-01       Impact factor: 12.701

7.  Tumour tissue microenvironment can inhibit dendritic cell maturation in colorectal cancer.

Authors:  Adriana J Michielsen; Andrew E Hogan; Joseph Marry; Miriam Tosetto; Fionnuala Cox; John M Hyland; Kieran D Sheahan; Diarmuid P O'Donoghue; Hugh E Mulcahy; Elizabeth J Ryan; Jacintha N O'Sullivan
Journal:  PLoS One       Date:  2011-11-18       Impact factor: 3.240

8.  Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes.

Authors:  C Alfaro; N Suarez; A Gonzalez; S Solano; L Erro; J Dubrot; A Palazon; S Hervas-Stubbs; A Gurpide; J M Lopez-Picazo; E Grande-Pulido; I Melero; J L Perez-Gracia
Journal:  Br J Cancer       Date:  2009-03-10       Impact factor: 7.640

  8 in total
  14 in total

1.  Pre-treatment of mice with tumor-conditioned media accelerates metastasis to lymph nodes and lungs: a new spontaneous breast cancer metastasis model.

Authors:  Esak Lee; Niranjan B Pandey; Aleksander S Popel
Journal:  Clin Exp Metastasis       Date:  2013-08-21       Impact factor: 5.150

2.  Polymer-loaded hydrogels serve as depots for lactate and mimic "cold" tumor microenvironments.

Authors:  Riley Allen; Emilie Ivtchenko; Bhasirie Thuamsang; Rapeepat Sangsuwan; Jamal S Lewis
Journal:  Biomater Sci       Date:  2020-10-01       Impact factor: 6.843

3.  Induction of dendritic cell maturation in the skin microenvironment by soluble factors derived from colon carcinoma.

Authors:  Jelle J Lindenberg; Rieneke van de Ven; Dinja Oosterhoff; Claudia C Sombroek; Sinéad M Lougheed; Anita G M Stam; Hans J P M Koenen; Alfons J M van den Eertwegh; Rik J Scheper; Tanja D de Gruijl
Journal:  Hum Vaccin Immunother       Date:  2014-04-14       Impact factor: 3.452

4.  [Blocking programmed death-ligand 1 attenuates maturation inhibition of dendritic cells by co-cultured breast cancer cells].

Authors:  Xiao-Ran Yu; Qiao-Sheng Wen; Yi Xiao; Rui Tang; Fu-Xi Li; Wen-Feng Shao; Yan-Lin Yu; Jing-Bo Xiong
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-05-20

Review 5.  Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy.

Authors:  Youra Kim; Derek R Clements; Andra M Sterea; Hyun Woo Jang; Shashi A Gujar; Patrick W K Lee
Journal:  Viruses       Date:  2015-12-09       Impact factor: 5.048

6.  Preclinical validation of the small molecule drug quininib as a novel therapeutic for colorectal cancer.

Authors:  Adrian G Murphy; Rory Casey; Aoife Maguire; Miriam Tosetto; Clare T Butler; Emer Conroy; Alison L Reynolds; Kieran Sheahan; Diarmuid O'Donoghue; William M Gallagher; David Fennelly; Breandán N Kennedy; Jacintha O'Sullivan
Journal:  Sci Rep       Date:  2016-10-14       Impact factor: 4.379

7.  The tumour microenvironment of the upper and lower gastrointestinal tract differentially influences dendritic cell maturation.

Authors:  Maria E Morrissey; Róisín Byrne; Celina Nulty; Niamh H McCabe; Niamh Lynam-Lennon; Clare T Butler; Susan Kennedy; Dermot O'Toole; John Larkin; Paul McCormick; Brian Mehigan; Mary-Clare Cathcart; Joanne Lysaght; John V Reynolds; Elizabeth J Ryan; Margaret R Dunne; Jacintha O'Sullivan
Journal:  BMC Cancer       Date:  2020-06-17       Impact factor: 4.430

8.  Tumor-altered dendritic cell function: implications for anti-tumor immunity.

Authors:  Kristian M Hargadon
Journal:  Front Immunol       Date:  2013-07-11       Impact factor: 7.561

9.  Growth differentiation factor-15 suppresses maturation and function of dendritic cells and inhibits tumor-specific immune response.

Authors:  Zhizhong Zhou; Weina Li; Yang Song; Lili Wang; Kuo Zhang; Jing Yang; Wei Zhang; Haichuan Su; Yingqi Zhang
Journal:  PLoS One       Date:  2013-11-13       Impact factor: 3.240

10.  Real-time metabolic profiling of oesophageal tumours reveals an altered metabolic phenotype to different oxygen tensions and to treatment with Pyrazinib.

Authors:  Amy M Buckley; Margaret R Dunne; Maria E Morrissey; Susan A Kennedy; Aoife Nolan; Maria Davern; Emma K Foley; Niamh Clarke; Joanne Lysaght; Narayanasamy Ravi; Dermot O'Toole; Finbar MacCarthy; John V Reynolds; Breandán N Kennedy; Jacintha O'Sullivan
Journal:  Sci Rep       Date:  2020-07-21       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.